|
Oct 9
|
BioAtla Inc (BCAB) Q2 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges
|
|
Oct 4
|
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
|
|
Oct 1
|
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
|
|
Aug 28
|
BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
|
|
Aug 8
|
Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
|
|
Jul 31
|
These 2 “Strong Buy” Penny Stocks Are Poised for a Big Rally, Say Analysts
|
|
Jul 25
|
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
|
|
Jul 24
|
BioAtla receives FDA fast track designation for ozuriftamab vedotin
|
|
Jul 23
|
BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
|
|
May 29
|
BioAtla to Participate in the Jefferies Global Healthcare Conference
|
|
May 23
|
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
May 23
|
Institutional owners may consider drastic measures as BioAtla, Inc.'s (NASDAQ:BCAB) recent US$35m drop adds to long-term losses
|
|
May 15
|
BioAtla Inc (BCAB) (Q1 2024) Earnings Call Transcript Highlights: Strategic Adjustments and ...
|
|
May 14
|
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
|
|
May 8
|
BioAtla to Participate in the Citizens JMP Life Sciences Conference
|
|
May 7
|
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
|
|
May 6
|
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
|
|
Apr 24
|
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
Mar 28
|
We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully
|
|
Mar 27
|
BioAtla, Inc. (NASDAQ:BCAB) Q4 2023 Earnings Call Transcript
|